Azetukalner is a small molecule commercialized by Xenon Pharmaceuticals, with a leading Phase III program in Tonic-Clonic (Grand Mal) Seizure;Partial Seizure. According to Globaldata, it is involved in 11 clinical trials, of which 5 were completed, 5 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Azetukalner’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Azetukalner is expected to reach an annual total of $145 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Azetukalner Overview
Azetukalner (XEN-1101, 1OP-2198) is under development for the treatment of partial seizure (focal-onset seizures), tonic-clonic (grand mal) seizure and major depressive disorder. The drug candidate is a small molecule administered orally as powder-in-capsule formulation. It acts by targeting potassium voltage-gated channel subfamily KQT Member 2 and 3 (KCNQ2/3). It was also under development for the treatment of neuro-ophthalmology disorders.
Xenon Pharmaceuticals Overview
Xenon Pharmaceuticals (Xenon) is a clinical-stage biopharmaceutical company that develops innovative therapeutics for neurological disorders. The company’s pipeline products include XEN1101, NBI-921352, and XEN496. XEN1101 is a differentiated Kv7 potassium channel opener under development to treat focal onset seizures, major depressive disorder and primary generalized tonic-clonic seizures. NBI-921352 and XEN496 are under development for treating focal-onset seizures in adults, pediatric epilepsy and orphan pediatric epilepsy. The company collaborates with other pharmaceutical companies for the development of therapeutic drug candidates. It operates in Canada and the US. Xenon is headquartered in Burnaby, British Columbia, Canada.
The operating loss of the company was US$214.1 million in FY2023, compared to an operating loss of US$129.1 million in FY2022. The net loss of the company was US$182.4 million in FY2023, compared to a net loss of US$125.4 million in FY2022.
For a complete picture of Azetukalner’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
